Trial

NAD-precursor combination in physically compromised older adults

Source-reviewedGoverned LongevityNext intelligence profile

Evidence reviewed through2026-08-07

Executive intelligence snapshot

Current reviewed view

Preclinical NAD biology motivated testing precursor supplementation in older adults with impaired physical function.

This profile includes 2 reviewed relationship(s) and 2 reviewed source(s).

This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.

Evidence state

Source-reviewed

Evidence reviewed through2026-08-07

Evidence state

What the evidence supports

Preclinical NAD biology motivated testing precursor supplementation in older adults with impaired physical function.

Evidence boundary

Key limitations

The publication reported no mitochondrial or skeletal-muscle function improvement, while the registry separately records early operational termination after COVID-19 disruption.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.

Not established

Key unknowns

Unreported or unaccepted endpoints, effect estimates, population details, dose, route, and post-freeze results remain unknown.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.

Next evidence milestone

What would change this view?

No specific evidence milestone is recorded yet.

Evidence reviewed through 2026-08-07.

Intelligence connections

Linked company

Maastricht University

Company

Tests

L-tryptophan, nicotinic acid, and nicotinamide

Intervention

Reviewed source layer

Evidence & sources

These cards show only metadata present in the reviewed source registry.

trial registry

NAD Supplementation Study in Physically Compromised Older Adults

ClinicalTrials.gov

Reference: NCT03310034

Reviewed: 2026-08-06

bibliographic index

NAD+-Precursor Supplementation Does Not Improve Mitochondrial or Skeletal Muscle Function in Physically Compromised Older Adults

PubMed

Reference: 34191033

Reviewed: 2026-08-06

Evidence update

Pending review

Further evidence review is pending.

Technical provenance

Object key: trial:LNPG-ENT-66a8c4ff-2cc2-4413-8e8f-3c143cba34fc
Source release: LNPG-REL-20260807-027
Mapping version: 0.2.0
Presentation release: LNPG-REL-20260808-037
Projection hash: 5dc57f7e4e39ed7b9579414b6699d3ba43b31a4f67edd16643fcf72e897c8f65

Source identifiers

LNPG-SRC-2123dfdc-71ef-4efa-a5d5-900ece47358e
LNPG-SRC-2146e2fb-d1e2-436e-98b7-e514464a9968

Directed relationship identities

edge:00291 — trial_exactly_links_company
edge:00292 — trial_tests_intervention

Scores are not displayed because no score methodology is qualified for this profile.

Presentation contract

Snapshot mode: DIRECT_GOVERNED_SUMMARY

Pending-state records

pending:00038 — accepted_downstream_pending_context
Exposed separately; canonical facts unchanged.
pending:00039 — accepted_downstream_pending_context
Exposed separately; canonical facts unchanged.